Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Notarangelo et al. reveal that the oncometabolite d-2-hydroxyglutarate, which is released in high quantities by tumour cells, is taken up by CD8+ T cells in the tumour microenvironment and blocks their proliferation and cytotoxicity by inhibition of lactate dehydrogenase and metabolic reprogramming.
In two studies published concurrently, Dohlman et al. and Narunsky-Haziza et al. have found strong correlative links between the prevalence of fungal DNA and cancer.
In this Tools of the Trade article, Daniela S. Thommen describes the development and use of a patient-derived tumour fragment (PDTF) platform wherein surgically resected tumour lesions are cultured ex vivo, which enables patients’ responses to immunotherapy to be more faithfully modelled.
In this Tools of the Trade article, Luigi Ombrato describes the development of Cherry-niche, a cell labelling system, which enables the unbiased identification of cancer cell-neighbouring cells.
In this Tools of the Trade article, Venkataramani describes the development of in vivo imaging workflows that allow the acquisition of imaging data with improved signal-to-noise matched to single-cell RNA-sequencing data.
‘Ductal carcinoma in situ’ (DCIS) describes abnormal cells in the milk ducts. DCIS is often non-invasive, although a small proportion of cases leave the ducts and progress to invasive breast cancer. This Review discusses the existing data for distinguishing progressive and non-progressive DCIS, with a focus on informing current disease management strategies.
Three-dimensional bioprinted cancer models could revolutionize understanding and treatment of cancer. Neufeld, Yeini and Pozzi discuss how such models can reveal novel biomarkers and drug targets, illuminate mechanisms of tumorigenesis and interactions between tumour, stromal and immune cells, and advance personalized cancer therapy.
This Perspective outlines the preclinical emergence of smart cell therapeutics, which when paired with machine learning analysis of genomic data could be implemented in the clinic to both enhance tumour recognition and prevent tumour escape.
The gut microbiota has been shown to regulate responses to various cancer therapies, and the microbial species involved and their underlying mechanisms have begun to be unravelled. In this Perspective, Fernandes and colleagues present this evidence and then outline how it could be used to develop microbiota-based therapies for patients with cancer.
